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Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most highly malignant and lethal cancers of the world.
Its pathogenesis has been reported to be multi-factorial, and the molecular carcinogenesis of HCC can not be
attributed to just a few individual genes. Based on the microRNA and mRNA expression profiling of normal liver
tissues, pericancerous hepatocellular tissues and hepatocellular carcinoma tissues, we attempted to find prognosis
related gene sets for HCC patients.
Results: We identified differentially expressed genes (DEG) from three comparisons: Cancer/Normal, Cancer/
Pericancerous and Pericancerous/Normal. GSEA (gene set enrichment analysis) were performed. Based on the
enriched gene sets of GO terms, pathways and transcription factor targets, it was found that the genome instability
and cell proliferation increased while the metabolism and differentiation decreased in HCC tissues. The expression
profile of DEGs in each enriched gene set was used to correlate to the postoperative survival time of HCC patients.
Nine gene sets were found to prognostic correlation. Furthermore, after substituting DEG-targeting-microRNA for
DEG members of each gene set, two gene sets with the microRNA expression profiles were obtained that had
prognostic potential.
Conclusions: The malignancy of HCC could be represented by gene sets, and pericancerous liver exhibits
important characteristics of liver cancer. The expression level of gene sets not only in HCC but also in the
pericancerous liver showed potential for prognosis implying an option for HCC prognosis at an early stage.
Additionally, the gene-targeting-microRNA expression profiles also showed prognostic potential, demonstrating
that the multi-factorial molecular pathogenesis of HCC is contributed by various genes and microRNAs.
Background
Hepatocellular carcinoma (HCC), is the sixth most preva-
lent cancer and the third most frequent cause of cancer-
related death [1]. More than 50% of the world’s HCC
cases occur in China (age-standardized incidence rate:
men, 35.2/100 000; women, 13.3/100 000) [2]. The patho-
genesis of HCC has been reported to be multi-factorial
[3,4]. Liver cirrhosis is the most important risk factor for
HCC [1], which occurs in 80%-90% of HCC patients [5].
In China, chronic hepatitis B virus (HBV) infection is
another major risk factor [6], which occurs in approxi-
mately 85% of HCC patients [7]. Additionally, the great
majority of HBV-infected HCC patients (70% and 90%)
have coexisting cirrhosis [2].
The complex process of molecular pathogenesis in HCC
also indicates that it is caused by multiple types of genes
during its development and progression. For years, the
combination of microarray and bioinformatics analytical
tools have been widely used to find differentially expressed
genes in hepatocellular carcinoma and to find differential
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diagnostic and prognostic markers [8-15]. Many such
studies have used pericancerous liver tissue (assumed to
be normal) as the control when selecting differentially
changed genes in HCC [8-13]. However, because most
pericancerous tissue of HCC is cirrhotic, this assumption
could miss important basal molecular changes in the can-
cer microenvironment. Scientists also attempted to look
for differentially expressed genes for prognosis in cirrhosis
[15] and non-cancerous liver tissues [14]. As we and other
researchers have discovered, dynamic dysregulation exists
in the development from cirrhosis to HCC [16], and differ-
entially expressed microRNA in peri-cancer has been used
for the prognosis of HCC patients [17].
The low survival rate of HCC patients is largely attribu-
ted to the high metastasis rate of HCC. Early studies
showed that molecular changes in primary HCC tissue
already implied future distant metastasis potential [13].
Additionally, the metastases were reported to be influ-
enced by liver microenvironment that can be represented
by inflammation/immune response-related signatures of
differentially expressed genes [14]. It would be very inter-
esting to know what kind of molecular changes in the
pericancerous tissue of HCC also bear a prediction poten-
tial for survival.
In this work, by applying gene expression profiling in
hepatocellular carcinoma and pericancerous hepatocellular
tissues from HCC patients and in normal liver tissues
from healthy individuals, we made an effort to investigate
the functional transition in pericancerous liver and cancer
liver in HCC patients. We identified expression-changed
genes in pericancerous liver and HCC tissue. Then,
we conducted functional enrichment analyses to demon-
strate the mechanism causing these transitional molecular
changes. Additionally, we checked the relationship
between the expression level of differentially expressed
members of each gene set and the postoperative survival
time of HCC patients. We found nine gene sets to be
potential prognostic markers. Furthermore, according to
the targeting relationships between genes and microRNAs,
we also substituted microRNAs for the gene members of
each gene set, and we attempted to predict the prognosis
with the expression level of the microRNAs that target dif-
ferentially expressed members of gene sets. Two prog-
nosis-related microRNA sets were identified.
Methods
Ethics statement
All human materials were obtained according to consent
regulation and approved by the Ethical Review Committee
of the World Health Organization Collaborating Center
for Human Products Research (authorized by Shanghai
Municipal Government). The individuals in this manu-
script have given written informed consent to publish
these case details.
Expression profile of mRNA and microRNA
The expression profiling of mRNA and microRNA were
performed on three types of liver tissues: HCC, pericancer-
ous liver and normal liver. Forty-five pairs of homogenous
human primary hepatocellular carcinoma and adjacent
pericancerous liver tissues were collected from the surgical
specimen archives of the Department of Pathology, First
Affiliated Hospital of Zhejiang University (Hangzhou City,
Zhejiang Province, China) and Qidong Liver Cancer Insti-
tute (Qidong City, Jiangsu Province, China). The perican-
cerous liver tissues were collected three centimeters away
from any liver tumor. Phenotypic information was col-
lected from patients’ records (Additional file 1). And none
of the HCC patients had received chemotherapy prior to
surgical operation. Ten normal liver tissues were obtained
from persons who died in traffic accidents. All of these tis-
sues were freshly frozen at -80°C and confirmed by a
pathologist. In each tissue, the total RNA was extracted by
TRIzol reagent (Invitrogen, CA, USA); the gene expression
was profiled by CapitalBio Human 22k oligonucleotide
microarray ([GEO:GPL5918]); and the microRNA expres-
sion was profiled by CapitalBio Mammalian miRNA Array
Services V1.0 ([GEO:GPL6542]). The expression profiling
by array is deposited in Gene Expression Omnibus (GEO)
[18] with the accession numbers [GEO:GSE45114]
(mRNA) and [GEO:GSE10694] (microRNA) [17].
Differentially expressed genes
Differentially expressed genes (DEG) involved in three
comparisons (Cancer/Normal, Cancer/Pericancerous and
Pericancerous/Normal) were detected by the limma
[19,20] package in Bioconductor [21] with absolute log2-
fold-change > 2 and adjusted p-value < 0.001, which was
adjusted by Benjamini and Hochberg’s method (BH) [22].
These three groups of DEGs (C/N_all, C/P_all and
P/N_all) were further separated into smaller groups, up-
regulated DEGs and down-regulated DEGs: C/N_up and
C/N_down; C/P_up and C/P_down; and P/N_up and
P/N_down.
Gene set enrichment analysis
Gene set enrichment analysis for each group of DEGs was
performed by the HTSanalyzeR [23] package in Bioconduc-
tor with the collection of annotated gene sets provided by
the Molecular Signatures Database [24] (MSigDB v4.0,
released Jun 7, 2013, including 10295 records). The MSigDB
collects various types of gene set, including seven major col-
lections: c1, chromosome and cytogenetic band; c2, online
pathway database, publications in PubMed, and knowledge
of domain experts, its CP sub-collection collected 1320
Canonical pathways derived from the pathway databases of
BioCarta [25], KEGG [26], PID [27], Reactome [28] and
four others (SigmaAldrich [29], Signaling Gateway [30], Sig-
nal Transduction KE [31], SuperArray [32]); c3, conserved
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cis-regulatory motifs, its TFT sub-collection collected 615
gene sets that contain genes sharing a transcription factor
binding site defined in the TRANSFAC (version 7.4) data-
base; c4, computational gene sets defined by mining large
collections of cancer-oriented microarray data; c5, gene
ontology, collected 1454 gene sets derived from the con-
trolled vocabulary of the Gene Ontology (GO) project [33];
c6, oncogenic signatures; and c7, immunologic signatures.
Only when the BH-adjusted p-values from a hypergeo-
metric test and Gene Set Enrichment Analysis (GSEA) [24]
were both lower than 0.05 was the gene set thought to be
significantly enriched with this group of DEGs.
MicroRNAs that target differentially expressed genes
By the RmiR [34] package in Bioconductor, we obtained
the targeting relationships between microRNAs and genes
that appear in at least three microRNA target databases
from six: miRBase [35], TargetScan [36], miRanda [37],
tarBase [38], mirTarget2 [39] and PicTar [40]. Then, we
obtained the set of microRNAs that target differentially
expressed genes in each gene set.
Association between gene (or microRNA) expression
profile and postoperative survival time
We used either the DEGs in each enriched gene set or the
microRNAs that target DEGs in each enriched gene set to
comprise a candidate classifier for prognosis. The associa-
tions between gene (or microRNA) expression and post-
operative survival time were tested by the phenoTest [41]
package in Bioconductor. The effects of the gene expres-
sion (or microRNA expression) on survival were tested via
the Cox proportional hazards model [42] and Kaplan-
Meier estimator [43]. Additionally, these associations were
validated on two independent data sets: [GEO:GSE14520]
[44,45] (including gene expression profiles of 227 pairs of
cancer and pericancerous liver samples, as well as 2 nor-
mal liver samples), and the liver hepatocellular carcinoma
tumor type from The Cancer Genome Atlas [46] (TCGA
LIHC) (including gene and microRNA expression profiled
with RNASeq from 27 pairs of cancer and pericancerous
liver tissues). The phenotypic information of 227 patients
from [GEO:GSE14520] and 27 patients from TCGA LIHC
are provided in Additional file 1.
Results
Differentially expressed genes
With the threshold of absolute log2-fold-change > 2 and
adjusted p-value < 0.001, totally 551 differentially expressed
genes (DEG) were identified from three comparisons,
Cancer/Normal (C/N, 479 DEGs), Cancer/Pericancerous
(C/P, 234 DEGs) and Pericancerous/Normal (P/N, 76
DEGs) (Additional file 2). And subgroups of DEGs from
each comparison were selected with up or down regulation
of DEGs (Figure 1). In Figure 1, sum of the “up_regulated
DEGs” (322) and “down-regulated DEGs” (233) are more
than “all DEGs” (555 vs. 551), because some genes were
up-regulated in one comparison but down-regulated in
another, such as EGR1 listed in Figure 1D, and they
appeared in both Figure 1B and 1C.
Among the 551 DEGs, six genes were differentially
expressed in all three comparisons (Figure 1). From
Figure 1D, DKK1, GABRE, HKDC1 and LRRC1 were up-
regulated in pericancerous liver and more up-regulated
in cancer liver. The DKK1 is a Wnt pathway inhibitor,
promoting invasion and metastasis of HCC [47], and a
serum biomarker for HCC diagnosis [48]. Although the
other three DEGs have not been reported in HCC, they
are disease related. GABRE is related to migraine suscept-
ibility [49]. HKDC1 is related to Alzheimer disease [50].
And LRRC1 is DNA repair related [51]. We think they
may be important in HCC carcinogenesis. On the con-
trary, KCNN2 was down-regulated in pericancerous and
more down-regulated in cancer liver. Since KCNN2 is
important for mediating the increase of transepithelial
secretion in biliary epithelial cells and prominently
expressed in intact liver [52], it seems some function of
normal liver was gradually suppressed in pericancerous
and cancer liver. And EGR1 was more up-regulated in
pericancerous liver but less up-regulated in cancer liver.
Considering that EGR1 is required for differentiation
and mitogenesis [53], the cell proliferation might be up-
regulated in both HCC and pericancerous liver, while
differentiation might be kept in pericancerous liver but
suppressed in HCC.
Gene sets enriched with differentially expressed genes
Gene set enrichment analysis was performed to identify
DEG-related functional gene sets. For each subgroup of
DEGs in Figure 1, the gene set enrichment analysis (by
hypergeometric test and GSEA) was run on 10295 anno-
tated gene sets in MSigDB v4.0, and a small part of them
were enriched with the nine subgroups of DEGs (see the
nine circles in Figure 1 A, B and C). The intersections of
gene sets enriched with different groups of DEGs were
counted in a Venn diagram (Additional file 3). Most gene
sets were enriched with both C/N DEGs and C/P DEGs.
Especially, the gene sets enriched with both C/N_up DEGs
and C/P_up DEGs (or both C/N_down DEGs and
C/P_down DEGs) showed the characters present in peri-
cancerous liver but more dys-regulated in HCC. Thus they
would provide us some clues about the gradual carcino-
genesis of liver tissue.
We further focused on detailed functional analyses of
gene sets enriched in three categories of MsigDB v4.0 col-
lection: c5, Gene Ontology (GO) sets; c2, Canonical path-
way sets; and c3, transcription factor targets gene sets
(TFT). There are 19 GO terms enriched with both
C/N_up and C/P_up DEGs (Additional file 4, 5), including
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biological process (BP) related to “cell cycle” and “mitosis”,
as well as cellular component (CC) related to “chromo-
some” and “spindle”, showing us the character of cell
proliferation that is closely related to carcinogenesis.
Meanwhile, 21 GO terms were enriched with both
C/N_down and C/P_down DEGs (Additional file 4, 5),
including various “metabolism” related BP, CC and MF
(molecular function), indicating that metabolisms were
disturbed in pericancerous liver and more so in HCC.
Similarly, there are 24 pathways that were enriched with
both C/N_up and C/P_up DEGs (Additional file 4, 5).
Keywords such as “Cell Cycle”, “G1”, “S”, “G2”, “M” and
Figure 1 Venn diagram of differently expressed genes (DEGs) from three comparisons. Venn diagram of differently expressed genes (DEGs)
from three comparisons: Cancer/Normal (C/N), Pericancerous/Normal (P/N) and Cancer/Pericancerous (C/P). A. Venn diagram of all DEGs from three
comparisons. The purple number in the center showed the number of DEGs appeared in all three comparisons. B. Venn diagram of up-regulated DEGs
from three comparisons. The red number in the center showed the number of DEGs appeared in all three comparisons. C. Venn diagram of down-
regulated DEGs from three comparisons. The blue number in the center showed the number of DEGs appeared in all three comparisons. D. The log2-
fold-change of DEGs in centers of subgraph A, B and C. The DEGs in red were appeared in the centers of subgraph A and B. The DEGs in blue were
appeared in the centers of subgraph A and C. The DEGs in purple was only appeared in the center of subgraph A.
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“Replication” indicate the genome instability and cell pro-
liferation hallmark of cancer cells [54] being activated. The
“p53” and “p73” related pathways indicate DNA damage
and apoptosis found in tumorigenesis. At the same time,
the ATR (ataxia telangiectasia and Rad3-related [55]) path-
way, PLK1 (polo-like kinase 1 [56]) pathway and the Fan-
coni anemia pathway showed the ability to repair DNA
damage in cancer cells. Thus, as a hallmark of HCC, cell
proliferation is the result of rebalancing between active
apoptosis by DNA damage and active survival by DNA
damage repair. Twenty-one pathways were enriched with
both C/N_down and C/P_down DEGs (Additional file 4,
5). The most repetitive keywords are “Metabolism” and
“PID_HNF3BPATHWAY” (transcription factor network
of FOXA2 and FOXA3), hinting that the function of meta-
bolism regulation and the potential for differentiation
were abnormal in HCC, because FOXA2 (forkhead box A2
[57]) and FOXA3 (forkhead box A3 [58]) are hepatocyte
nuclear factors that act as transcriptional activators for
liver-specific genes such as albumin and transthyretin.
Similar results have been found in mice [59].
Not only GO and pathway gene sets, but the transcrip-
tion factor targets gene sets (TFTs) also provided func-
tional annotations for DEGs. We found 19 TFTs were
enriched with both C/N_up and C/P_up DEGs (Additional
file 4, 5), with the cell cycle controlling transcription factor
E2F family being the most conspicuous factor. And E2F3
and E2F8 were over-expressed in HCC indeed (Additional
file 2). At the same time, only one TFT “RGTTAMW-
NATT_V$HNF1_01” was enriched with both C/N_down
and C/P_down DEGs (Additional file 4, 5).
From the gene ontology, pathway and transcription fac-
tor targets related gene sets enriched with both C/N DEGs
and C/P DEGs, we found that during cancer progress of
HCC, cell proliferation was gradually up-regulated while
metabolism was progressively down-regulated. It is rare to
observe such phenomena with direct proofs, the advantage
stem from our gene expression profiling of gradually chan-
ging samples: from normal, to pericancerous, to cancerous
liver tissues.
Association between gene expression profile and
postoperative survival time
It is understandable that transitional molecular changes
represented by gene sets may demonstrate mechanistic
trend of development from normal tissue to cancer tissue,
however, whether such changes can be prognostic may be
another question.
The DEGs in each enriched gene set might comprise a
candidate gene classifier for prognosis. We tested the asso-
ciation between the expression of these candidate gene
classifiers and postoperative survival time in our data set,
which was 45 HCC patients from [GEO:GSE45114]. Nine
gene sets with the expression level of DEGs that associated
with the postoperative survival time in our dataset were
also validated in [GEO:GSE14520] (227 HCC patients)
(Table 1). As shown in Table 1, Figure 2, 3 and Additional
file 6, the expression profile of sets of DEGs in HCC, even
pericancerous liver could be used for prognosis.
The first three gene sets in Table 1 showed prognosis
potential with up-regulated DEGs in cancer liver. Their
DEG members expression level in cancer could be used
for prognosis in both our 45 HCC patients from [GEO:
GSE45114] and the 227 HCC patients from [GEO:
GSE14520] (P < 0.05 and HR > 0). The positive HR (hazard
ratio) means the higher DEGs expression the worse the
prognosis. In Figure 2, we show the prognosis ability of
nine DEGs in gene set “chr1q32” which was reported to be
the most recurrently gained genomic region in HCC [60].
Another gene set “KAUFFMANN_MELANOMA_RELAP-
SE_UP” [61] contains DNA repair and replication related
genes (Additional file 6).
The next three gene sets in Table 1 showed prognosis
potential of pericancerous liver with up-regulated DEGs.
Gene set “BROWNE_HCMV_INFECTION_2HR_UP”
contains genes that were related to hepatic inflammation
and cirrhosis [62]. Their expression level may represent
not only inflammation and cirrhosis but also carcinogen-
esis of HCC (Figure 3). And the gene set “ENK_UV_RE-
SPONSE_EPIDERMIS_DN” [63] contains genes related to
DNA damage repair (Additional file 6).
Besides up-regulated DEGs, the down-regulated DEGs
in cancer liver also showed prognosis potential in the last
three gene sets (Table 1 and Additional file 6). Here, nega-
tive HR (hazard ratio) means the lower DEG expression
the worse the prognosis.
In summary, prognosis of HCC patients could be pre-
dicted with expression profiles of both up-regulated DEGs
and down-regulated DEGs enriched in certain functional
gene sets.
Association between microRNA expression profile and
postoperative survival time
Gene sets enriched with DEGs either in C/N, C/P or P/N
were shown to have prognosis potential, as reported
above. MicroRNA profiling data is also available for the
45 HCC patients with paired pericancer/cancer samples.
Since microRNA expression signatures in hepatocellular
carcinoma have been stated to possess prognostic value
before [17,64], we would like to see in our work, whether
DEGs related microRNA sets could be prognostic. We
identified the targeting relationships between microRNAs
and genes that appear in at least three microRNA target
databases from six: miRBase [35], TargetScan [36], miR-
anda [37], tarBase [38], mirTarget2 [39] and PicTar [40].
The microRNAs that target DEGs in each enriched gene
set comprise a candidate microRNA set for prognosis
prediction. Then we tested the association between the
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expression of these microRNAs and postoperative survi-
val times in our 45 patients from [GEO:GSE10694]. Two
prognostic microRNA gene sets were validated in an
independent test dataset TCGA LIHC (27 HCC patients
with RNASeq data) (Table 2).
Gene set “SMID_BREAST_CANCER_BASAL_DN”
contains genes that are down-regulated in basal subtype
of breast cancer samples [65]. We found that 32 member
genes were down-regulated in HCC relative to normal
liver and nine of them were targeted by 37 microRNAs.
The 37 microRNAs expression profile in cancer liver
could be used for prognosis (Figure 4). The positive HR
(hazard ratio) means the higher expression the worse
prognosis.
The other gene set “SMID_BREAST_CANCER_LUMI-
NAL_B_UP” contains genes that are up-regulated in the
luminal B subtype of breast cancer [65]. Its 12 member
genes were down-regulated in HCC relative to normal
liver and four of them were targeted by 22 microRNAs.
The 22 microRNAs expression profile in the cancer liver
could be used for prognosis (Additional file 6). Interest-
ingly, the four DEGs are subset of the nine DEGs men-
tioned in above gene set (Table 2), which shows the
similarity and difference between basal subtype and lumi-
nal subtype of breast cancers.
Most of the microRNAs listed in Table 2 have been
annotated to be related to HCC in The human micro-
RNA disease database (HMDD) [66] (Additional file 7).
Such as the cell proliferation related microRNAs: hsa-
mir-18a, hsa-mir-93, hsa-mir-96; and cancer recurrence
related microRNAs: hsa-mir-148a, hsa-mir-18a, hsa-mir-
18b, hsa-mir-19a, hsa-mir-22, hsa-mir-221, hsa-mir-222,
hsa-mir-96. In Table 2 there are some microRNAs have
not been recorded to be HCC related by HMDD,
including: hsa-miR-136, hsa-miR-206, hsa-miR-26b, hsa-
miR-302a, hsa-miR-302d, hsa-miR-340, hsa-miR-410,
hsa-miR-488, hsa-miR-495, hsa-miR-506. They may be
potentially HCC related.
Discussion
There have been numerous studies of hepatocellular carci-
noma(HCC) in comparison with pericancerous tissue as
normal control, in the purpose of identifying differentially
expressed genes, modules, networks etc., in order to find
cancer biomarkers, cluster samples, or to predict prog-
nosis. Such studies especially on Chinese HCC patient
samples take on a strong assumption that pericancerous
liver tissue of HCC is normal, while this in a large percen-
tage is wrong. Most patients diagnosed with HCC in
China already went through years of liver cirrhotic change
because of chronic HBV infection, alcoholism, or fatty
liver etc. Therefore, in this work of ours, we designed a set
of normal liver tissues as control. With such a design, we
were able to identify differentially expressed genes (DEGs)
with a gradual up-regulation from normal to pericancer-
ous to cancerous liver, or DEGs with a gradual down-
regulation. Further gene set enrichment analysis (GSEA)
on GO terms, pathway, and transcription factor targets
suggested the main up-regulated trend to be in cell cycle
and proliferation, and the main down-regulated trend to








chr1q32 C/N_up 9 BATF3, C1orf106, CENPF, MDM4, NEK2, RABIF, TLR5, TRAF5,
UBE2T
C
KAUFFMANN_MELANOMA_RELAPSE_UP C/N_up 12 CENPF, CHEK1, CHEK2, FANCD2, GINS2, MCM6, MSH2,




5 BUB1B, CCNE2, CDK1, MCM6, TOP2A C & C/P
BROWNE_HCMV_INFECTION_2HR_UP P/N_up 4 EGR1, FOS, NR4A2, NR4A3 P/N
ENK_UV_RESPONSE_EPIDERMIS_DN P/N_up 10 AREG, CH25H, EGR1, EGR2, FJX1, GSN, LXN, NR4A2, PTGS2,
STK17B
P/N
GSE9988_LOW_LPS_VS_CTRL_TREATED_MONOCYTE_UP P/N_up 8 AREG, EGR1, IL6, NR4A2, NR4A3, PTGS2, RGS1, SERPINB8 P/N
MODULE_43 C/N_down 17 ACADL, ACADSB, CAT, CYP1A1, CYP26A1, CYP2C8, CYP3A4,
CYP3A7, CYP4A11, DAO, ETFDH, FMO3, GYS2, LEPR,
PPP1R1A, QDPR, TREH
C
MODULE_99 C/N_down 17 ABAT, AFM, BBOX1, BCHE, CRHBP, F11, FETUB, IGF1, LEPR,
LIFR, MARCO, NAT2, OTC, PCK1, SLC10A1, SLC22A1, UGT8
C/N
PKCA_DN.V1_UP C/N_down 17 ADRA1A, BBOX1, CYP2C18, CYP2C8, DIO1, FBP1, LECT2,
NR1I3, PCK1, PIPOX, PRODH2, RDH16, RDH5, SEC14L2,
SLC2A2, TREH, UPB1
C
*"Profile": the expression profile used for prognosis; “C” means the absolute expression value of genes in cancer; while “C/P” and “P/N” mean the relative gene
expression level of cancer/pericancerous liver and pericancerous/normal liver respectively.
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be metabolism. Although such conclusions may not be
totally novel, it is nice to see such direct proof of gradual
molecular transitions in liver carcinogenesis. More in-
depth detailed analyses of the gradually changed gene sets
may even lead to clues for early diagnosis, however it is
beyond the scope of this paper’s discussion.
Instead, we made efforts to testify whether gene sets
enriched with gradually changing DEGs have prognostic
value. Many previous researches proposed lists of DEGs,
pathways, network modules (the latter two can be consid-
ered as gene sets) to predict prognosis for HCC patients.
We used somewhat a combined approach. Instead of
Figure 2 Prognosis with DEGs in gene set “chr1q32”. Gene set “chr1q32” could be used for prognosis with DEG members’ expression levels
in HCC. Kaplan-Meier survival curves and heatmaps of the correlation between the postoperative survival time and the expression profile of
differentially expressed gene members in the gene set “chr1q32” with the DEG expression levels in HCC. A. Kaplan-Meier survival curve of DEG
expression levels in 45 HCC patients from [GEO:GSE45114]. B. Kaplan-Meier survival curve of DEG expression levels in 227 HCC patients from
[GEO:GSE14520]. C. Heatmap of DEG expression levels from [GEO:GSE45114]. D. Heatmap of DEG expression levels from [GEO:GSE14520]. The
positive HR (hazard ratio) means the worse prognosis with the higher expression. UBE2T did not appear in subgraph D because this gene was
not detected in [GEO:GSE14520]. The remaining DEGs still show significant potential for prognosis.
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using groups of single DEGs that would lack functional
binding, or full gene sets that would contain too many
genes, we used DEGs grouped in preselected enriched
gene sets as classifiers. The advantage is that the classifier
is relatively small, and the DEGs share a common gene
function family. Indeed we were able to identify nine such
gene set DEGs classifiers possessing prognostic prediction
power, and could even be validated in an independent
dataset with larger patient number. Quite a few such gene
sets behold cell proliferation or DNA repair functions in
liver cancer tissues, or inflammation function in perican-
cerous liver tissues.
Figure 3 Prognosis with DEGs in gene set “BROWNE_HCMV_INFECTION_2HR_UP”. Gene set “BROWNE_HCMV_INFECTION_2HR_UP” could
be used for prognosis with DEG members’ expression levels in ratio of Pericancerous/Normal. Kaplan-Meier survival curves and heatmaps of the
correlation between the postoperative survival time and the expression profile of differentially expressed gene members in the gene set
“BROWNE_HCMV_INFECTION_2HR_UP” with the DEG expression levels in the ratio of Pericancerous/Normal. A. Kaplan-Meier survival curve of
DEG expression levels in 45 HCC patients from [GEO:GSE45114]. B. Kaplan-Meier survival curve of DEG expression levels in 227 HCC patients from
[GEO:GSE14520]. C. Heatmap of DEG expression levels from [GEO:GSE45114]. D. Heatmap of DEG expression levels from [GEO:GSE14520].
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MicroRNA (miRNA) as a new kind of regulatory bio-
marker, has been investigated in many cancers in recent
years. In our previous works, individual miRNAs and
miRNA regulatory network modules have been success-
fully applied in HCC prognosis prediction [17,67,68]. In
this work, we took a simple approach. Since some of the
gene sets enriched with gradually changing DEGs in liver
carcinogenesis have been proved to possess prognosis
potential, we substituted such gene sets with miRNAs tar-
geting the DEGs they contained. To ensure the substitu-
tions are relevant all miRNA-DEG target relationships
must be carefully curated from multiple databases and
prediction algorithms. Two gene sets substituted with
miRNAs acquired prognostic power, and could be vali-
dated in a TCGA RNASeq dataset which has miRNA
expression data of paired HCC samples available. This
may actually represent a simple approach to quickly dis-
cover relevant miRNAs which might have caused the dys-
regulation of the DEGs that are associated with prognosis.
Traditionally differentially expressed miRNAs should first
be detected and secondly correlated to their downstream
targets and further to functional applications.
Figure 1 and Additional file 3 indicated the similarities
between pericancerous and normal liver, when comparing
to HCC. This proves the rationality for many researchers
who take pericancerous tissues as control. Similarly,
researchers found that gene expression pattern is more
significantly related to physiological condition rather than
tissue spatial distance [69]. They reported that different
cancer tissues may show common gene expression pat-
terns. Our results might provide an evidence for that:
some prognosis biomarkers we found in HCC also play
important roles in other cancers, such as melanoma and
breast cancer (Additional file 6 and Figure 4). At the same
time, we found that pericancerous liver shared some
characters of HCC, which provided the probability for
prognosis prediction with gene expression profiles of peri-
cancerous liver (Figure 3 and Additional file 6).
There are of course limitations to our work. The
patient sample size is not big, and the normal samples
are from healthy individuals who died accidentally,
rather than real normal liver sample of the same HCC
patient, which is hardly possible to get. Therefore the
gradual changes from normal to pericancerous to can-
cerous liver tissues observed in this dataset may not be
very steady accessible features that can be easily applied
clinically. However our strategy does put an emphasis
on the importance to study the cirrhotic and inflamma-
tic nature of pericancerous tissue in HCC patients,
which show both carcinogenesis trend and prognostic
potential. In the future, integrating sequence informa-
tion from DNASeq and RNASeq as well as clinical
information in bigger sample size data sets may benefit
such purpose.
Conclusions
In this work, Based on differentially expressed genes
(DEGs) detected from normal, pericancerous, cancerous
liver samples by array technology, and the annotated
gene sets from GSEA MSigDB, we managed to show
some molecular transitional changes represented by dif-
ferent GO, pathway, regulatory gene sets. DEGs profile
of nine of such gene sets could be applied to predict
hepatocellular carcinoma (HCC) patient survival. Two
gene sets acquired prognostic capacity after being sub-
stituted with microRNAs targeting the DEGs contained
in the original gene set. Both gene set prognosis and
miRNA set prognosis were validated with independent
HCC patients gene expression or RNASeq dataset. Our
work represents an effort to study pericancerous nature
of HCC, and a simple way to identify relevant regulatory
miRNAs to DEGs.
Table 2 Gene sets associated to postoperative survival time with microRNA expression profile (validated in TCGA
LIHC).
Gene set * DEG microRNAs targeting to DEG Count
SMID_BREAST_CANCER_BASAL_DN ABAT ASPA CXCL14 ESR1
FAM134B IGF1 PBLD PCK1
SORD
hsa-let-7b, hsa-miR-130a, hsa-miR-130b, hsa-miR-136, hsa-miR-148a,
hsa-miR-148b, hsa-miR-152, hsa-miR-181c, hsa-miR-181d, hsa-miR-182,
hsa-miR-18a, hsa-miR-18b, hsa-miR-19a, hsa-miR-206, hsa-miR-22, hsa-
miR-221, hsa-miR-222, hsa-miR-26b, hsa-miR-29a, hsa-miR-29c, hsa-
miR-302a, hsa-miR-302b, hsa-miR-302c, hsa-miR-302d, hsa-miR-31, hsa-
miR-340, hsa-miR-372, hsa-miR-373, hsa-miR-410, hsa-miR-425, hsa-






SMID_BREAST_CANCER_LUMINAL_B_UP ABAT ESR1 FAM134B SORD hsa-miR-130a, hsa-miR-130b, hsa-miR-148a, hsa-miR-148b, hsa-miR-
152, hsa-miR-181c, hsa-miR-181d, hsa-miR-182, hsa-miR-18a, hsa-miR-
18b, hsa-miR-19a, hsa-miR-22, hsa-miR-221, hsa-miR-222, hsa-miR-






*These two gene sets were both enriched with C/N_down group DEGs. And the absolute expression value of microRNA in cancer, which detected by array in
[GEO:GSE10694] or by RNASeq in TCGA LIHC were used for prognosis.
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Figure 4 Prognosis with DEG-members-targeting-microRNAs in gene set “SMID_BREAST_CANCER_BASAL_DN”. Gene set
“SMID_BREAST_CANCER_BASAL_DN” could be used for prognosis with DEG-members-targeting-microRNA expression levels in HCC. Kaplan-Meier
survival curves and heatmaps of the correlation between the postoperative survival time and the expression profile of microRNAs that target
differentially expressed gene members in the gene set “SMID_BREAST_CANCER_BASAL_DN”. A. Kaplan-Meier survival curve of DEG-targeting-
microRNA expression levels in 45 HCC patients from [GEO:GSE10694]. B. Kaplan-Meier survival curve of DEG-targeting-microRNA expression levels
in 27 HCC patients from TCGA LIHC. C. Heatmap of DEG-targeting-microRNA expression levels from [GEO:GSE10694]. D. Heatmap of DEG-
targeting-microRNA expression levels from TCGA LIHC.
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Additional material
Additional file 1: Tables, phenotypic data of HCC patients.
Phenotypic data of: 45 patients from [GEO:GSE45114] and [GEO:
GSE10694]; 227 patients from [GEO:GSE14520]; 27 patients from TCGA
LIHC.
Additional file 2: Tables, DEGs and gene sets enriched with DEGs.
The 551 identified differentially expressed genes (DEGs) of three
comparisons: Cancer/Normal (C/N), Cancer/Pericancerous (C/P) and
Pericancerous/Normal (P/N). The value “NA” means that this gene (row
head) is not a DEG in this comparison (column head). And the 868 non
repetitive gene sets that enriched with the nine groups of DEGs (nine
circles in Figure 1) by both two enrich method (hypergeometric test and
GSEA). The value “NA” means that this gene set (row head) is not
enriched with this group of DEGs (column head).
Additional file 3: Figure, venn diagram of gene sets enriched with
DEGs from three comparisons. Venn diagram of gene sets enriched
with DEGs from three comparisons: Cancer/Normal (C/N), Pericancerous/
Normal (P/N) and Cancer/Pericancerous (C/P). A. Venn diagram of gene
sets enriched with the all DEGs from three comparisons. B. Venn diagram
of gene sets enriched with the up-regulated DEGs from three
comparisons. The red number showed the number of gene sets
enriched with both C/N_up DEGs and C/P_up DEGs. C. Venn diagram of
gene sets enriched with the down-regulated DEGs from three
comparisons. The blue number showed the number of gene sets
enriched with both C/N_down DEGs and C/P_down DEGs. D. Counts of
gene ontology, pathway and transcription factor targets gene sets
enriched with both C/N DEGs and C/P DEGs. The numbers in red were
covered by red number in subgraph B. The numbers in blue were
covered by blue number in subgraph C.
Additional file 4: Figures, venn diagram of GOs, Pathways and TFTs
enriched with DEGs from three comparisons. Venn diagram of gene
sets about gene ontology terms (GO), Pathways and Transcription factor
targets (TFT) enriched with DEGs from three comparisons: Cancer/Normal
(C/N), Pericancerous/Normal (P/N) and Cancer/Pericancerous (C/P). A.
Venn diagram of gene sets enriched with the all DEGs from three
comparisons. B. Venn diagram of gene sets enriched with the up-
regulated DEGs from three comparisons. The red number showed the
number of gene sets enriched with both C/N_up DEGs and C/P_up
DEGs. C. Venn diagram of gene sets enriched with the down-regulated
DEGs from three comparisons. The blue number showed the number of
gene sets enriched with both C/N_down DEGs and C/P_down DEGs.
Additional file 5: Tables, gene sets enriched with both C/N DEGs
and C/P DEGs. Gene sets about Gene ontology terms (GOs), Pathways
and Transcription factor targets gene sets (TFTs) enriched with both C/N
DEGs and C/P DEGs.
Additional file 6: Figures, gene sets used for prognosis with
expression profile of DEG members. Kaplan-Meier survival curves and
heatmaps of the correlation between the postoperative survival time and




“MODULE_99” and “PKCA_DN.V1_UP”. Each figure includs four subgraphs:
A. Kaplan-Meier survival curve of DEG expression levels in 45 HCC patients
from [GEO:GSE45114]. B. Kaplan-Meier survival curve of DEG expression
levels in 227 HCC patients from [GEO:GSE14520]. C. Heatmap of DEG
expression levels in 45 HCC patients from [GEO:GSE45114]. D. Heatmap of
DEG expression levels in 227 HCC patients from [GEO:GSE14520]. And the
Kaplan-Meier survival curves and heatmaps of the correlation between the
postoperative survival time and expression profile of DEG-targeting
microRNAs in gene set “SMID_BREAST_CANCER_LUMINAL_B_UP” which
validated with 27 HCC patients from TCGA LIHC. Including four subgraphs:
A. Kaplan-Meier survival curve of DEG expression levels in 45 HCC patients
from [GEO:GSE10694]. B. Kaplan-Meier survival curve of DEG expression
levels in 27 HCC patients from TCGA LIHC. C. Heatmap of DEG expression
levels in 45 HCC patients from [GEO:GSE10694]. D. Heatmap of DEG
expression levels in 27 HCC patients from TCGA LIHC. (Note: The positive
HR (hazard ratio) means the higher expression the worse prognosis. While
the negative HR (hazard ratio) means the lower expression the worse
prognosis. Some genes may not appear in subgraph D, because those
genes (or microRNAs) were not detected in [GEO:GSE14520] (or TCGA
LIHC). The remaining DEGs (or microRNAs) still show significant potential
for prognosis.)
Additional file 7: Table, microRNAs annotation recorded by the
human microRNA disease database (HMDD). Most microRNAs listed in
Table 2 have been annotated by the human microRNA disease database
(HMDD). The table list the 27 HCC related microRNAs with their
references and descriptions annotated by HMDD.
List of abbreviations used
HCC: Hepatocellular carcinoma; DEG: Differentially expressed genes; GSEA:
Gene set enrichment analysis; GEO: Gene expression omnibus; MSigDB:
Molecular signatures database; GO: Gene ontology; TCGA: The cancer
genome atlas; LIHC: Liver hepatocellular carcinoma; C/N: Cancer/Normal; C/P:
Cancer/Pericancerous; P/N: Pericancerous/Normal; TFT: Transcription factor
targets; HR: Hazard ratio; HMDD: Human microRNA disease database.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LW performed the analyses of this research and drafted the manuscript. BL
participated in microRNA targeting, and revision of manuscript. YZ
participated in gene set enrichment analysis. WL participated in survival
analysis. JG designed this work. XH participated in design and revision. LX
participated in design and wrote part of the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
Written consent was obtained from the patient or their relative for
publication for this study. This work was supported by grants from the
National 973 Key Basic Research Program (2013CB910500), the National
Natural Science Foundation of China (81125016, 81071637, 91029728) and
the Key Infectious Disease Project [2012ZX10002012-014].
Declarations
Publication of this article was funded by State Key Laboratory of Oncogenes
and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao
Tong University School of Medicine.
This article has been published as part of BMC Genomics Volume 15
Supplement 1, 2014: Selected articles from the Twelfth Asia Pacific
Bioinformatics Conference (APBC 2014): Genomics. The full contents of the
supplement are available online at http://www.biomedcentral.com/
bmcgenomics/supplements/15/S1.
Authors’ details
1Shanghai Medical College, Fudan University, Shanghai 200032, P. R. China.
2State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer
Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine,
Shanghai 200032, P. R. China. 3Shanghai Center for Bioinformation
Technology, Shanghai Academy of Science and Technology, Shanghai
201203, P. R. China. 4School of Life Sciences and Biotechnology, Shanghai
Jiao Tong University, Shanghai 200240, P. R. China.
Published: 24 January 2014
References
1. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012,
379:1245-1255.
2. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and
molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
3. Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR:
Genetics of hepatocellular carcinoma. World J Gastroenterol WJG 2007,
13:2271-2282.
4. Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human
hepatocellular carcinoma. Nat Genet 2002, 31:339-346.
Wei et al. BMC Genomics 2014, 15(Suppl 1):S13
http://www.biomedcentral.com/1471-2164/15/S1/S13
Page 11 of 13
5. Fattovich G, Stroffolini T, Zagni I, Donato F: Hepatocellular carcinoma in
cirrhosis: incidence and risk factors. Gastroenterology 2004, 127(5 Suppl 1):
S35-50.
6. Kumagi T, Hiasa Y, Hirschfield GM: Hepatocellular carcinoma for the non-
specialist. BMJ 2009, 339:b5039.
7. Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, Inoue M:
Hepatitis B and C virus infection and hepatocellular carcinoma in China:
a review of epidemiology and control measures. J Epidemiol Jpn
Epidemiol Assoc 2011, 21:401-416.
8. Choi JK, Choi JY, Kim DG, Choi DW, Kim BY, Lee KH, Yeom YI, Yoo HS,
Yoo OJ, Kim S: Integrative analysis of multiple gene expression profiles
applied to liver cancer study. FEBS Lett 2004, 565:93-100.
9. Neo SY, Leow CK, Vega VB, Long PM, Islam AFM, Lai PBS, Liu ET, Ren EC:
Identification of discriminators of hepatoma by gene expression
profiling using a minimal dataset approach. Hepatol Baltim Md 2004,
39:944-953.
10. Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y,
Inazawa J, Miki Y, Tanaka H: Aurora kinase B is a predictive factor for the
aggressive recurrence of hepatocellular carcinoma after curative
hepatectomy. Br J Surg 2008, 95:611-619.
11. Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong WM, Xia Y, Zou QF, Xi T, Shen F,
Wang HY, Wu MC: Overexpression of aspartyl-(asparaginyl)-beta-
hydroxylase in hepatocellular carcinoma is associated with worse
surgical outcome. Hepatol Baltim Md 2010, 52:164-173.
12. Yang JD, Sun Z, Hu C, Lai J, Dove R, Nakamura I, Lee JS, Thorgeirsson SS,
Kang KJ, Chu IS, Roberts LR: Sulfatase 1 and sulfatase 2 in hepatocellular
carcinoma: associated signaling pathways, tumor phenotypes, and
survival. Genes Chromosomes Cancer 2011, 50:122-135.
13. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, Li Y, Robles AI,
Chen Y, Ma ZC, Wu ZQ, Ye SL, Liu YK, Tang ZY, Wang XW: Predicting
hepatitis B virus-positive metastatic hepatocellular carcinomas using
gene expression profiling and supervised machine learning. Nat Med
2003, 9:416-423.
14. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y,
Qin LX, Tang ZY, Wang XW: Prediction of venous metastases, recurrence,
and prognosis in hepatocellular carcinoma based on a unique immune
response signature of the liver microenvironment. Cancer Cell 2006,
10:99-111.
15. Paradis V, Bièche I, Dargère D, Laurendeau I, Laurent C, Bioulac Sage P,
Degott C, Belghiti J, Vidaud M, Bedossa P: Molecular profiling of
hepatocellular carcinomas (HCC) using a large-scale real-time RT-PCR
approach: determination of a molecular diagnostic index. Am J Pathol
2003, 163:733-741.
16. Huang T, Liu L, Liu Q, Ding G, Tan Y, Tu Z, Li Y, Dai H, Xie L: The role of
Hepatitis C Virus in the dynamic protein interaction networks of
hepatocellular cirrhosis and carcinoma. Int J Comput Biol Drug Des 2011,
4:5-18.
17. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z,
Hu X, Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D,
Yang S, Li Y, Gu J: Diagnostic and prognostic implications of microRNAs
in human hepatocellular carcinoma. Int J Cancer 2008, 123:1616-1622.
18. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene
expression and hybridization array data repository. Nucleic Acids Res 2002,
30:207-210.
19. Smyth GK: Limma: linear models for microarray data. Bioinforma Comput
Biol Solut Using R Bioconductor New York: Springer; 2005, 397-420.
20. Smyth GK: Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol
2004, 3:Article3.
21. Bioconductor. [http://www.bioconductor.org].
22. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: A Practical
and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol
1995, 57:289-300.
23. Wang X, Terfve C, Rose JC, Markowetz F: HTSanalyzeR: an R/Bioconductor
package for integrated network analysis of high-throughput screens.
Bioinforma Oxf Engl 2011, 27:879-880.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA,
Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: Gene set
enrichment analysis: a knowledge-based approach for interpreting
genome-wide expression profiles. Proc Natl Acad Sci USA 2005,
102:15545-15550.
25. BioCarta. [http://www.biocarta.com].
26. Kanehisa M, Goto S: KEGG: Kyoto Encyclopedia of Genes and Genomes.




30. Signaling Gateway. [http://www.signaling-gateway.org].
31. Signal Transduction KE. [http://stke.sciencemag.org].
32. SuperArray. [http://www.superarray.com].
33. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP,
Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A,
Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene
ontology: tool for the unification of biology. The Gene Ontology
Consortium. Nat Genet 2000, 25:25-29.
34. Francesco F: RmiR: Package to work with miRNAs and miRNA targets
with R. R package version 1.16.0..
35. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: tools for
microRNA genomics. Nucleic Acids Res 2008, 36(Database):D154-158.
36. Garcia DM, Baek D, Shin C, Bell GW, Grimson A, Bartel DP: Weak seed-
pairing stability and high target-site abundance decrease the proficiency
of lsy-6 and other microRNAs. Nat Struct Mol Biol 2011, 18:1139-1146.
37. Betel D, Wilson M, Gabow A, Marks DS, Sander C: The microRNA.org
resource: targets and expression. Nucleic Acids Res 2008, 36(suppl 1):
D149-D153.
38. Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P, Hatzigeorgiou AG:
The database of experimentally supported targets: a functional update
of TarBase. Nucleic Acids Res 2009, 37(Database):D155-158.
39. Wang X: miRDB: a microRNA target prediction and functional annotation
database with a wiki interface. RNA N Y N 2008, 14:1012-1017.
40. PicTar. [http://pictar.mdc-berlin.de].
41. Planet E: phenoTest: Tools to test association between gene expression
and phenotype in a way that is efficient, structured, fast and scalable.
We also provide tools to do GSEA (Gene set enrichment analysis) and
copy number variation.. R package version 1.6.0. 2010.
42. Cox D: Regression models and life-tables. J R Stat Soc Ser B 1972,
34:187-220.
43. Kaplan EL, Meier P: Nonparametric Estimation from Incomplete
Observations. J Am Stat Assoc 1958, 53:457.
44. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS,
Sun Z, Tang ZY, Qin LX, Wang XW: A unique metastasis gene signature
enables prediction of tumor relapse in early-stage hepatocellular
carcinoma patients. Cancer Res 2010, 70:10202-10212.
45. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, Walker R, Jia HL, Ye QH,
Qin LX, Tang ZY, He P, Hunter KW, Thorgeirsson SS, Meltzer PS, Wang XW:
Integrative genomic identification of genes on 8p associated with
hepatocellular carcinoma progression and patient survival.
Gastroenterology 2012, 142:957-966.e12.
46. The Cancer Genome Atlas (TCGA). [http://cancergenome.nih.gov].
47. Tao YM, Liu Z, Liu HL: Dickkopf-1 (DKK1) promotes invasion and
metastasis of hepatocellular carcinoma. Dig Liver Dis Off J Ital Soc
Gastroenterol Ital Assoc Study Liver 2013, 45:251-257.
48. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J,
Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J,
Wang H, Qin W: Serum DKK1 as a protein biomarker for the diagnosis of
hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol
2012, 13:817-826.
49. Fernandez F, Esposito T, Lea RA, Colson NJ, Ciccodicola A, Gianfrancesco F,
Griffiths LR: Investigation of gamma-aminobutyric acid (GABA) A
receptors genes and migraine susceptibility. BMC Med Genet 2008, 9:109.
50. Grupe A, Li Y, Rowland C, Nowotny P, Hinrichs AL, Smemo S,
Kauwe JSK, Maxwell TJ, Cherny S, Doil L, Tacey K, van Luchene R,
Myers A, Wavrant-De Vrièze F, Kaleem M, Hollingworth P, Jehu L, Foy C,
Archer N, Hamilton G, Holmans P, Morris CM, Catanese J, Sninsky J,
White TJ, Powell J, Hardy J, O’Donovan M, Lovestone S, Jones L, et al: A
scan of chromosome 10 identifies a novel locus showing strong
association with late-onset Alzheimer disease. Am J Hum Genet 2006,
78:78-88.
51. Svendsen JM, Smogorzewska A, Sowa ME, O’Connell BC, Gygi SP,
Elledge SJ, Harper JW: Mammalian BTBD12/SLX4 assembles a Holliday
junction resolvase and is required for DNA repair. Cell 2009,
138:63-77.
Wei et al. BMC Genomics 2014, 15(Suppl 1):S13
http://www.biomedcentral.com/1471-2164/15/S1/S13
Page 12 of 13
52. Feranchak AP, Doctor RB, Troetsch M, Brookman K, Johnson SM, Fitz JG:
Calcium-dependent regulation of secretion in biliary epithelial cells: the
role of apamin-sensitive SK channels. Gastroenterology 2004, 127:903-913.
53. Sukhatme VP, Cao XM, Chang LC, Tsai-Morris CH, Stamenkovich D,
Ferreira PC, Cohen DR, Edwards SA, Shows TB, Curran T: A zinc finger-
encoding gene coregulated with c-fos during growth and
differentiation, and after cellular depolarization. Cell 1988, 53:37-43.
54. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell
2011, 144:646-674.
55. Cimprich KA, Shin TB, Keith CT, Schreiber SL: cDNA cloning and gene
mapping of a candidate human cell cycle checkpoint protein. Proc Natl
Acad Sci USA 1996, 93:2850-2855.
56. Holtrich U, Wolf G, Bräuninger A, Karn T, Böhme B, Rübsamen-Waigmann H,
Strebhardt K: Induction and down-regulation of PLK, a human serine/
threonine kinase expressed in proliferating cells and tumors. Proc Natl
Acad Sci USA 1994, 91:1736-1740.
57. Wang H, Gauthier BR, Hagenfeldt-Johansson KA, Iezzi M, Wollheim CB:
Foxa2 (HNF3beta ) controls multiple genes implicated in metabolism-
secretion coupling of glucose-induced insulin release. J Biol Chem 2002,
277:17564-17570.
58. Mincheva A, Lichter P, Schütz G, Kaestner KH: Assignment of the human
genes for hepatocyte nuclear factor 3-alpha, -beta, and -gamma
(HNF3A, HNF3B, HNF3G) to 14q12-q13, 20p11, and 19q13.2-q13.4.
Genomics 1997, 39:417-419.
59. Wolfrum C, Shih DQ, Kuwajima S, Norris AW, Kahn CR, Stoffel M: Role of
Foxa-2 in adipocyte metabolism and differentiation. J Clin Invest 2003,
112:345-356.
60. Kim TM, Yim SH, Shin SH, Xu HD, Jung YC, Park CK, Choi JY, Park WS,
Kwon MS, Fiegler H, Carter NP, Rhyu MG, Chung YJ: Clinical implication of
recurrent copy number alterations in hepatocellular carcinoma and
putative oncogenes in recurrent gains on 1q. Int J Cancer J Int Cancer
2008, 123:2808-2815.
61. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A,
Dessen P, van den Oord JJ, Spatz A, Sarasin A: High expression of DNA
repair pathways is associated with metastasis in melanoma patients.
Oncogene 2008, 27:565-573.
62. McCaughan GW, Gorrell MD, Bishop GA, Abbott CA, Shackel NA,
McGuinness PH, Levy MT, Sharland AF, Bowen DG, Yu D, Slaitini L,
Church WB, Napoli J: Molecular pathogenesis of liver disease: an
approach to hepatic inflammation, cirrhosis and liver transplant
tolerance. Immunol Rev 2000, 174:172-191.
63. Enk CD, Jacob-Hirsch J, Gal H, Verbovetski I, Amariglio N, Mevorach D,
Ingber A, Givol D, Rechavi G, Hochberg M: The UVB-induced gene
expression profile of human epidermis in vivo is different from that of
cultured keratinocytes. Oncogene 2006, 25:2601-2614.
64. Wei RR, Huang GL, Zhang MY, Li BK, Zhang HZ, Shi M, Chen XQ, Huang L,
Zhou QM, Jia WHJ, Zheng XFS, Yuan YF, Wang HY: Clinical significance
and prognostic value of microRNA expression signatures in
hepatocellular carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res 2013.
65. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM, Foekens JA,
Martens JWM: Subtypes of breast cancer show preferential site of
relapse. Cancer Res 2008, 68:3108-3114.
66. Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, Cui Q: An Analysis of
Human MicroRNA and Disease Associations. PLoS ONE 2008, 3:e3420.
67. Zeng L, Yu J, Huang T, Jia H, Dong Q, He F, Yuan W, Qin L, Li Y, Xie L:
Differential combinatorial regulatory network analysis related to venous
metastasis of hepatocellular carcinoma. BMC Genomics 2012, , 13 Suppl 8:
S14.
68. Tu K, Yu H, Hua YJ, Li YY, Liu L, Xie L, Li YX: Combinatorial network of
primary and secondary microRNA-driven regulatory mechanisms. Nucleic
Acids Res 2009, 37:5969-5980.
69. Chen M, Xiao J, Zhang Z, Liu J, Wu J, Yu J: Identification of human HK
genes and gene expression regulation study in cancer from
transcriptomics data analysis. PloS One 2013, 8:e54082.
doi:10.1186/1471-2164-15-S1-S13
Cite this article as: Wei et al.: Application of microRNA and mRNA
expression profiling on prognostic biomarker discovery for
hepatocellular carcinoma. BMC Genomics 2014 15(Suppl 1):S13.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wei et al. BMC Genomics 2014, 15(Suppl 1):S13
http://www.biomedcentral.com/1471-2164/15/S1/S13
Page 13 of 13
